tor to IR. Adipose tissue, as an endocrine organ, produces several adipokines such as leptin and adiponectin, which are involved in modulation of insulin action in metabolic tissues such as skeletal muscle and the liver [4] . In addition, macrophages, which infiltrate adipose tissue, serve as a major source of locally produced proinflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), ultimately desensitizing insulin action [5] . Therefore, obesity can cause IR by altering adipokine profiles and causing an excess production of pro-inflammatory cytokines.
However, a substantial number of ESRD patients are not obese [6] . Interestingly, even in non-obese ESRD patients, IR is prevalent and an independent predictor of cardiovascular mortality [7] . There are a few possible explanations for this phenomenon. It is speculated that uremia-associated factors such as chronic inflammation are involved in the pathogenesis of IR [8] . Furthermore, circulating concentrations of adipok-and WC were measured with an empty peritoneal cavity after completion of dialysate drainage. All participants gave their written informed consent prior to study inclusion.
Data Collection
Demographic and clinical data were recorded at study entry. After an overnight fast, venous samples were drawn for assessment of the following laboratory data: hemoglobin, blood urea nitrogen (BUN), creatinine, albumin, calcium, phosphorus, intact parathyroid hormone (PTH), total cholesterol, low density lipoprotein (LDL)-cholesterol, high density lipoprotein (HDL)cholesterol, and triglyceride. The preceding overnight dwell was regulated to 1.5% dextrose dialysate to standardize the glucose load. Fasting concentrations of glucose, total cholesterol, HDL-and LDL-cholesterol, and triglyceride were measured with an auto-analyzer using an enzymatic colorimetric method (Hitachi 7150, Hitachi Ltd., Tokyo, Japan). Cystatin C was measured by using a particle-enhanced nephelometric immunoassay (Dade Behring Ltd, Marburg, Germany). Nutritional status was determined using SGA score ines are markedly elevated in ESRD patients because of their decreased renal clearance [9] , and these altered adipokine profiles may worsen IR even in non-obese individuals. However, whether adipokines or inflammation play a role in the development of IR in these nonobese patients has not yet been explored. Therefore, in this study, we investigated the roles of adipokine and inflammation in IR in non-obese patients.
Subjects and Methods

Patients
This cross-sectional single-center study involved 135 ESRD patients receiving peritoneal dialysis (PD) at Yonsei University Severance Hospital, Seoul, Korea. In this study, PD patients were our particular concern. These individuals are at high risk of IR because a substantial amount of glucose is absorbed via the peritoneal capillary vessels, which elevates serum insulin level [10] . Patients were considered eligible if they aged 20 to 75 years and had maintained PD > 3 months. Any of the following criteria were excluded from participation; BMI >25 kg/m 2 , history of overt infections during the 3 months prior to the study, history of malignancy or other chronic inflammatory disease (e.g., rheumatoid arthritis or systemic lupus erythematosus), evidence of severe malnutrition with subjective global assessment (SGA) score ≤5 or serum albumin level <3.5 g/dL, prior history of kidney transplantation, current use of glucocorticoids or peroxisome proliferatoractivated receptor agonists that may affect adiponectin level. After excluding patients who met one of these criteria, a total of 62 patients were included ( Fig. 1) .
To assess obesity, we measured body mass index (BMI) and waist circumference (WC). However, in this study, we primarily used BMI as the indicator of obesity because WC may not reliably reflect abdominal visceral fat content in ESRD patients undergoing PD [11] . In addition, according to definition of obesity proposed by Korean Society for the Study of Obesity [12] , patients with BMI <25 kg/m 2 were considered non-obese because epidemiological studies of Asian populations have shown that the threshold values of anthropometric indices for association with cardiovascular risk factors are considerably lower than those conventionally used in Caucasians [13, 14] , and because strong evidence now shows that Asian people have more body fat than their Caucasian counterparts at the same BMI [15, 16] . Height, body weight,
Fig. 1 Flow diagram indicating patient recruitment and exclusion
ESRD, end-stage renal disease; PD, peritoneal dialysis; SGA, subjective global assessment; PPAR-γ, peroxisome proliferator activated receptor gamma; BMI, body mass index 4 hour as previously suggested [21] .
Statistical Analyses
Statistical analysis was performed using SPSS for Windows, version 13.0 (SPSS Inc., Chicago, IL, USA). All data are expressed as mean ± standard deviation (SD). The Kolmogorov-Smirnov test was used to analyze the normality of the distribution of the parameters measured. Data with a skewed distribution, such as HOMA-IR and hsCRP, were expressed as log transformations. Geometric means for all log-normally distributed continuous variables were calculated and reported with geometric SD. Data for RRF are presented as median values and interquartile ranges. For normally distributed data, variables were compared between two groups using Student's t-test and the Chi-square test. In addition, Pearson's correlation tests were used to evaluate the relationships between HOMA-IR and clinical and laboratory parameters. For skewed data, the Mann-Whitney U-test was conducted to compare variables between two groups, and Spearman's correlation coefficient was determined to identify the relationship between co-variates. To define independent factors associated with log-transformed HOMA-IR (log HOMA-IR), multiple linear regression analyses were conducted, using variables such as age, gender and other variables that were significantly associated with log HOMA-IR in correlation analyses. P-value <0.05 was considered statistically significant.
Results
Baseline Demographic, Clinical and Laboratory Findings
The baseline characteristics of the study patients are shown in Table 1 . The mean age was 48.6 years, 53.2% were male, and the mean PD duration was 73.2 months. Diabetic patients accounted for 6.5% of all patients. The average BMI was 21.6 kg/m 2 . Metabolic syndrome was present in 14 patients (22.6%) The mean systolic and diastolic blood pressures were 132.5 ± 18.2 and 79.9 ± 9.3 mmHg, respectively, and study patients were taking an average of 2.4 antihypertensive pills daily. The geometric mean values of HOMA-IR, leptin, and hsCRP were 2.07, 14.7 ng/mL, and 0.76 mg/L respectively, while the average adiponectin concentration was 17.7 µg/ml. We obtained data for HOMA-IR in healthy non-obese subjects (n = 30), who were recruited for an earlier study [22] . Compared with [17] . Definition of metabolic syndrome essentially followed that of the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) definition [18] . However, WC cutoff point for central obesity was defined to be 90 cm for men and 85 cm for women according to Korean Society for the Study of Obesity [12] .
Because the use of non-glucose based solution may lead to less glucose absorption via peritoneal cavity, we also evaluated icodextrin solution users, who were defined as one bag exchange of this solution per day for > 1 month before the study.
Measurement of Homeostasis Model Assessment of Insulin Resistance
From the serum fasting levels of glucose and insulin, the homeostatic model assessment -insulin resistance (HOMA-IR) was calculated according to the following formula [19] : glucose (mg/dL) X insulin (μIU/ ml)/405. Insulin levels were determined by chemiluminescent assay system (Immulite 2000, Los Angeles, CA, USA).
Measurement of Serum Inflammatory Markers and Adipokines
High-sensitivity C-reactive protein (hsCRP) concentration was measured using a latex-enhanced immunonephelometric method on a BN II analyzer (Dade Behring, Newark, DE, USA). The concentrations of IL-6, adiponectin (R&D Systems Europe, Abingdon, Oxon, UK), TNF-α, leptin (R&D Systems Inc., Minneapolis, MN, USA), and resistin (LINCO Research, St Charles, MS, USA) were measured using enzyme-linked immunosorbent assay (ELISA) kits. The ELISA system had an intra-assay coefficients of variability (CV) of 3.48% and an inter-assay CV of 4.36%.
Assessment of Dialysis Adequacy, Residual Renal Function, and Glucose Absorption
Urea kinetic studies were conducted using a 24-hour collection of dialysate and urine at the time of study enrollment. Dialysis adequacy was determined by measuring total weekly urea clearance (Kt/V urea ) using the Watson equation [20] , and residual renal function (RRF) was determined as the average of urea and creatinine clearance from a 24-hour urine collection. In addition, the amount of glucose absorption via peritoneal cavity was determined using the equation based on peritoneal equilibration test (PET) D/D0 glucose at tin, cystatin C did not differ between the two groups. Serum TNF-α levels were slightly elevated in the H group than in the L group, but it was not statistically significant. In addition, patients in the H group had significantly higher triglyceride levels (143.5 ± 65.7 vs. 103.4 ± 52.2 mg/dL, P = 0.010) than those in the L group. However, the proportion of icodextrin users, RRF, and the prevalence of metabolic syndrome were not different between the two groups. The amount of peritoneal glucose exposure and glucose absorption was slightly increased in the H group than in the L group, but it did not reach statistical significance.
Factors Associated with HOMA-IR
Bivariate correlation analyses were conducted to elucidate the relationships between HOMA-IR and other variables ( Table 2 and Fig. 2 ). Log HOMA-IR healthy controls, HOMA-IR was significantly higher in non-obese PD patients, suggesting that our study subjects had greater insulin-resistance than these healthy non-obese patients (2.07 ± 1.65 vs. 1.21 ± 0.85, P = 0.013, data not shown).
Comparisons of Demographic, Clinical and Laboratory Parameters According to HOMA-IR
Study patients were assigned to two groups according to median HOMA-IR. Demographic, clinical, and laboratory parameters were compared between the two groups ( Table 1) . Compared with patients with HOMA-IR <1.85 (L group), patients with HOMA-IR >1.85 (H group) had lower serum adiponectin levels (14.4 ± 8.8 vs. 21.1 ± 8.0 μg/mL, P = 0.003) and higher hsCRP levels (1.09 ± 3.09 vs. 0.54 ± 2.97 mg/L, P = 0.017), whereas serum concentrations of leptin, resis- To further identify factors that were independently associated with HOMA-IR, multiple linear regression analysis was conducted. Age, gender, and variables that were significantly correlated with HOMA-IR in the was inversely correlated with adiponectin (γ = -0.464, P < 0.001) and log HDL cholesterol (γ = -0.250, P = 0.050) but was positively related to age (γ = 0.334, P = 0.008), triglyceride (γ = 0.392, P = 0.002), and peritoneal glucose absorption (γ = 0.274, P = 0.031). However, log leptin and log hsCRP were not associated with log HOMA-IR.
In contrast, serum adiponectin level was negatively level. However, we failed to find any significant association between HOMA-IR and other adipokines or inflammatory cytokines. These findings suggest that, among these parameters, low circulating adiponectin level might play a role in the pathogenesis of IR in nonobese ESRD patients. Although IR is multifactorial in origin, obesity has long been linked with IR. In obesity, white adipose tissue serves as a major source of locally produced pro-inflammatory cytokines such as Il-6 and TNF-α [5] , which can alter insulin sensitivity by triggering key steps in the insulin signaling pathway. In addition, several adipokines derived from adipocytes are known to be involved in IR pathogenesis. Leptin increases in obesity because of leptin resistance [23] . Leptin can suppress insulin secretion from the pancreas [24] , and hyperleptinemia is observed in chronic kidney disease (CKD) patients with hyperinsulinemia [25] . In contrast, adiponectin, which has anti-inflammatory and insulin-sensitizing effects, decreases in obesity [26] . Taken together, inflammatory cytokines and altered adipokines from adipose tissue act together to hinder insulin action, resulting in an insulin resistant state. Interestingly, because adipokines are normally excreted by the kidney, their levels are elevated in ESRD patients, even if they are not obese [9, 27] . In addition, chronic inflammation is a key feature of CKD [28] . However, whether the effects of adipokines and vinflammation on IR exist in 'non-obese' ESRD patients is currently unknown. Therefore, investigating this issue is interesting because circulating levels in these patients are altered irrespective of obesity.
A major finding of our study is that adiponectin showed an independent and negative association with IR even in non-obese PD patients. This finding is in agreement with previous studies of ESRD patients that included both obese and non-obese patients [29, 30] . In addition, circulating adiponectin level was inversely associated with adverse metabolic risk factors [29, 30] , and its decreased level independently predicted cardiovascular outcome [29, 31] . This indicated that, even if adiponectin is elevated due to decreased renal clearance, low adiponectin level appears to be unfavorable in ESRD patients. Interestingly, an association between hypoadiponectinemia and IR was previously suggested in 'non-obese' patients without CKD [32] [33] [34] . In these studies, circulating adiponectin level was decreased and independently associated with IR parameters in non-obese but otherwise insu-bivariate correlation analyses were used to construct a multiple linear regression model. To address potential multicollinearity, variance inflation factors (VIF) were analyzed. We found no variables with VIF >10, suggesting that multicollinearity was unlikely. In our model, adiponectin (β ± SE, -0.023 ± 0.009; P = 0.015), DM (β ± SE, 0.664 ± 0.326; P = 0.047), and triglyceride (β ± SE, 0.003 ± 0.002; P = 0.026) were identified as independent factors associated with HOMA-IR (Table 3 ). This finding was corroborated by a separate analysis using the definition of obesity based on WC ( Table 4 ), suggesting that low circulating adiponectin levels were significantly associated with HOMA-IR.
Discussion
In this cross-sectional study of 62 'non-obese' PD patients, we showed that HOMA-IR was independently and negatively correlated with circulating adiponectin In addition to obesity, uremia-associated factors such as chronic inflammation or oxidative stress might contribute to IR in ESRD patients [8] . However, in the present study, we did not find that chronic inflammation was significantly associated with IR, although we observed a trend of positive correlation between hsCRP and HOMA-IR. This might stem from the fact that our study subjects had strongly attenuated inflammation. The mean concentration of hsCRP was 0.76 mg/L. This value is considerably lower than earlier reported [43] , given the fact that these non-obese patients of our study were undergoing PD. Interestingly, adiposity is reported to amplify inflammation and oxidative stress in CKD patients [43] . In addition, a Japanese study of 1,624 non-diabetic subjects found that the association between CRP and HOMA-IR was decreased after adjustment for BMI [44] . Therefore, in non-obese patients, inflammation might be lower, resulting in a weakened association with IR.
A unique feature of PD is a large amount of glucose absorption via peritoneal cavity. This may aggravate insulin resistance in PD patients. In this study, the amount of peritoneal glucose absorption was slightly elevated in patients with HOMA-IR > 1.85 than those with HOMA-IR < 1.85 (72.3 ± 16.9 vs. 80.0 ± 19.8 g/ day, P=0.104), and it was significantly correlated with log HOMA-IR (γ =0.274, P=0.031). However, peritoneal glucose absorption was not independently associated with HOMA-IR in the multivariate analysis. In addition, it was not significantly correlated with serum adiponectin levels. These findings suggest that insulin resistance is not entirely determined by peritoneal glucose absorption.
Several shortcomings of this study should be discussed. First, as a cross-sectional study at a single center, it was subject to biases inherent to this study design. In addition, a cross-sectional design does not allow for cause-and-effect relationships to be drawn between adiponectin and IR. In fact, despite the previously reported insulin-sensitizing effect of adiponectin [26] , circulating adiponectin level was reduced during hyperinsulinemic euglycemic clamp studies, suggesting a possible suppressive effect of insulin on adiponectin [45, 46] . Second, we used HOMA-IR as the IR indicator rather than the hyperinsulinemic euglycemic clamp test, which is regarded as the gold standard for measuring IR. However, this method is cumber-lin-resistant states. These findings suggest that hypoadiponectinemia might be involved in IR even in nonobese patients even though adiposity, which is a strong suppressor of adiponectin, is not evident. However, whether adiponectin is protective in non-obese uremic conditions requires further investigation.
Recently, high-molecular-weight (HMW) adiponectin is considered biologically active and it is reported that HMW-to-total adiponectin ratio (HMWR) was more predictive of insulin resistance and metabolic syndrome [35] . However, this finding was not replicated in a subsequent study by Bluher et al showing that HMWR was not superior to total adiponectin in assessing insulin sensitivity [36] . To explore this issue, we measured HMW adiponectin using ELSIA method and found that there was a highly significant correlation between HMW and total adiponectin (γ = 0.660, P <0.001). When HMWR was entered instead of total adiponectin in a multivariate regression analysis, it was independently correlated with HOMA-IR (β ± SE, -0.025 ± 0.007; P = 0.022, data not shown). In addition, the area under receiver operating characteristic curve of total adiponectin and HMWR for the prediction of HOMA-IR >1.85 was 0.66 and 0.68, respectively, suggesting that both forms of adiponectin was comparable in predicting insulin resistance.
In this study, leptin was not associated with IR. This finding contradicted the results of a previous study by Zoccali et al. showing that leptin positively correlated with HOMA-IR in ESRD patients undergoing hemodialysis [37] . This discrepancy could be explained by differences in the characteristics of study subjects and dialysis modalities. Our study included only nonoverweight and non-obese PD patients in whom the amount of adipose tissue was substantially decreased. Therefore, it can be surmised that less leptin was produced in the 'non-obese' condition. In fact, our study patients had relatively lower leptin levels than did ESRD patients in previous studies [9, 38, 39] . In addition, serum resistin level was not associated with IR in this study. Resistin is also secreted by adipocytes and its circulating level is increased in CKD patients [40] . Although a previous study suggested a potential link between obesity and IR [41] , subsequent studies did not find a significant association between resistin and IR in uremic patients [40, 42] . In line with these findings, serum resistin level did not correlate with HOMA-IR in our study. Taken together, it can be speculated that leptin and resistin do not contribute to IR in toneal cavity as aforementioned. Therefore, it needs to be verified whether our findings can be generalized to patients with HD.
In conclusion, this study showed that low circulating adiponectin level was independently associated with HOMA-IR in non-obese ESRD patients undergoing PD. Our findings also suggested that leptin and resistin from adipose tissue do not appear to contribute to IR in the non-obese condition even though their circulating concentrations were elevated due to decreased renal clearance, irrespective of obesity. some and inconvenient. HOMA-IR is reported to be well correlated with the hyperinsulinemic euglycemic test and has been validated in CKD patients [47] . Third, in this study, we primarily used BMI as an indicator of obesity. Recently, WC has been suggested as a better parameter of central obesity than BMI in the general population [48] . However, a concern in ESRD patients undergoing PD is that WC might not reliably reflect abdominal visceral fat content because of the presence of a Tenckhoff catheter in situ, lax skin after repeated distention of the abdomen by PD fluid, and potential residual peritoneal dialysate within the abdominal cavity. This renders measurement of WC inaccurate in this group. Nevertheless, to clarify this concern, we conducted a separate analysis using the definition of obesity based on WC. We found that an independent association between low adiponectin level and HOMA-IR still remained (Table 4 ). Finally, patients with hemodialysis were not included in this study. However, patients with PD were of our particular interest because they are more likely insulin resistant than those with HD due to large amount of glucose absorption via peri-
